Clinical Trial Update: Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas [Phase 2]

View source ↗

Summary

Phase 2 trial of antineoplaston therapy in recurrent or refractory mixed gliomas has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mixed Gliomas

Drugs mentioned

• Antineoplaston therapy

Snippet

Sponsor: Burzynski Research Institute | Conditions: Mixed Gliomas | Phase 2 | Status: COMPLETED | Results posted: 2016-11-01